AMENDMENTS TO THE CLAIMS

Please amend the claims as follows.

1. (Currently Amended) A compound of formula (I):

wherein:

x and v are each independently 1;

W is -O-, -C(O)O-, -N(R1)-, -S(O),- (where t is 0, 1 or 2), -N(R1)S(O)2-, -OC(O)- or

-C(O)-:

411728

 $\label{eq:viscosity} V\text{ is -C(O)-, -C(S)-, -C(O)N(R^1)-, -C(O)O-, -S(O)_2-, } \underline{or} -S(O)_2N(R^1)- er -C(R^{44})H-; \\ each \, R^1 \text{ is independently selected from the group consisting of hydrogen,} \\$

C1-C12alkyl, C2-C12hydroxyalkyl, C4-C12cycloalkylalkyl and C7-C19aralkyl;

 $R^2 \text{ is selected from the group consisting of } C_1\text{-}C_{12}\text{alkyl}, C_2\text{-}C_{12}\text{alkenyl}, \\ C_2\text{-}C_{12}\text{hydroxyalkyl}, C_2\text{-}C_{12}\text{hydroxyalkenyl}, C_2\text{-}C_{12}\text{alkoxyalkyl}, C_3\text{-}C_{12}\text{cycloalkyl}, \\ C_4\text{-}C_{12}\text{cycloalkylalkyl}, \text{aryl}, C_7\text{-}C_{19}\text{aralkyl}, C_3\text{-}C_{12}\text{heterocyclyl}, C_3\text{-}C_{12}\text{heterocyclylalkyl}, \\ C_4\text{-}C_{12}\text{cycloalkylalkyl}, \text{aryl}, C_7\text{-}C_{19}\text{aralkyl}, C_3\text{-}C_{12}\text{heterocyclyl}, C_3\text{-}C_{12}\text{heterocyclylalkyl}, \\ C_4\text{-}C_{12}\text{cycloalkylalkyl}, \text{aryl}, C_7\text{-}C_{19}\text{aralkyl}, C_3\text{-}C_{12}\text{heterocyclyl}, C_3\text{-}C_{12}\text{heterocyclylalkyl}, \\ C_4\text{-}C_{12}\text{-}C_{1$

 C_1 - C_{12} heteroaryl, and C_3 - C_{12} heteroarylalkyl, provided that when W is -O-, R^2 is not C_1 - C_{12} alkyl;

or R^2 is a multi-ring structure having 2 to 4 rings wherein the rings are independently selected from the group consisting of cycloalkyl, heterocyclyl, aryl and heteroaryl and where some or all of the rings may be fused to each other;

 R^3 is selected from the group consisting of $C_1\text{-}C_{12}$ alkyl, $C_2\text{-}C_{12}$ alkenyl, $C_2\text{-}C_{12}\text{-}hydroxyalkyl, C_2\text{-}C_{12}\text{-}hydroxyalkenyl, C_2\text{-}C_{12}\text{-}alkoxyalkyl, C_3\text{-}C_{12}\text{-}cycloalkyl,}\\ C_4\text{-}C_{12}\text{-}cycloalkylalkyl, aryl, $C_7\text{-}C_{19}\text{-}aralkyl, $C_3\text{-}C_{12}\text{-}heterocyclyl, $C_3\text{-}C_{12}\text{-}heterocyclylalkyl,}\\ C_1\text{-}C_{12}\text{-}heteroaryl and $C_3\text{-}C_{12}\text{-}heteroarylalkyl, provided that when V is $-C(O)$- or $-C(O)O$-, R^3 is not $C_1\text{-}C_{12}\text{-}alkyl;}$

or R³ is a multi-ring structure having 2 to 4 rings wherein the rings are independently selected from the group consisting of cycloalkyl, heterocyclyl, aryl and heteroaryl and where some or all of the rings may be fused to each other;

R⁴ and R⁵ are each independently selected from hydrogen, fluoro, chloro, methyl, methoxy, trifluoromethyl, cyano, nitro or -N(R¹³)₂;

 $R^6,\,R^{8a},\,R^7,\,R^{7a},\,R^8,\,R^{8a},\,R^9\,\text{and}\,\,R^{9a}\,\text{are each independently selected from hydrogen or}\,\,C_1\text{-}C_3\text{alkyl};}$

R14 is C1-C3alkyl; and

each R13 is independently selected from hydrogen or C₁-C₅alkyl;

a stereoisomer, enantiomer or tautomer thereof, a pharmaceutically acceptable salt thereof, a pharmaceutical composition thereof or a prodrug thereof.

2. - 9. (Canceled)

10. (Currently Amended) A compound of formula (la):

wherein:

x and y are each independently 1;

W is -O-, -C(O)O-, -N(R1)-, -S(O)_t- (where t is 0, 1 or 2), -N(R1)S(O)₂-, -OC(O)- or

-C(O)-;

 $\label{eq:Vision} V\text{ is -C(O)-, -C(S)-, -C(O)N(R^1)-, -C(O)O-, -S(O)_z-, }\underbrace{\text{or} -S(O)_zN(R^1)-\text{er--C(R^{44})H-;}}_{\text{each }R^1\text{ is independently selected from the group consisting of hydrogen,}$

C1-C12alkyl, C2-C12hydroxyalkyl, C4-C12cycloalkylalkyl and C7-C19aralkyl;

 R^2 is selected from the group consisting of C_1 - C_{12} alkyl, C_2 - C_{12} alkenyl, C_2 - C_{12} hydroxyalkyl, C_2 - C_{12} hydroxyalkenyl, C_2 - C_{12} alkoxyalkyl, C_3 - C_{12} cycloalkyl, C_3 - C_{12} cycloalkyl, C_3 - C_{12} -heterocyclyl, C_3 - C_{12} -heterocyclylalkyl, C_3 - C_{12} -heterocyclyl, C_3 - C_{12} -heterocyclylalkyl, C_3 - C_{12} -heteroaryl, and C_3 - C_{12} -heteroarylalkyl, provided that, when W is -C(O)-, R^2 can not be C_3 - C_4 -alkyl substituted by $-S(O)_1$, R^3 where R^{14} is hydrogen, C_1 - C_9 -alkyl, C_7 - C_{12} -aralkyl, pyrazinyl, pyridinonyl, pyrrolidionyl or imidazolyl, provided that when W is -O-, R^2 is not C_1 - C_{12} alkyl; or R^2 is a multi-ring structure having 2 to 4 rings wherein the rings are

independently selected from the group consisting of cycloalkyl, heterocyclyl, aryl and heteroaryl and where some or all of the rings may be fused to each other;

 $R^3 \ is \ selected \ from \ the \ group \ consisting \ of \ C_1-C_{12} alkyl, \ C_2-C_{12} alkenyl, \\ C_2-C_{12} hydroxyalkyl, \ C_2-C_{12} hydroxyalkenyl, \ C_2-C_{12} alkoxyalkyl, \ C_3-C_{12} cycloalkyl, \\ C_4-C_{12} cycloalkylalkyl, \ aryl, \ C_7-C_{19} aralkyl, \ C_3-C_{12} heterocyclyl, \ C_3-C_{12} heterocyclylalkyl, \\ C_1-C_{12} heteroaryl \ and \ C_3-C_{12} heteroarylalkyl, \ provided \ that \ when \ V \ is \ -C(O)- \ or \ -C(O)O-, \ R^3 \ is \ not \ C_7-C_{12} alkyl;$

or R³ is a multi-ring structure having 2 to 4 rings wherein the rings are independently selected from the group consisting of cycloalkyl, heterocyclyl, aryl and heteroaryl and where some or all of the rings may be fused to each other;

R⁴ and R⁵ are each independently selected from hydrogen, fluoro, chloro, methyl, methoxy, trifluoromethyl, cyano, nitro or -N(R¹³)₂;

 R^8 , R^{8a} , R^7 , R^{7a} , R^8 , R^{8a} , R^9 and R^{9a} are each independently selected from hydrogen or C_1 - C_3 alkví:

R11-is-C4-C3alkyl; and

each R¹³ is independently selected from hydrogen or C₁-C₀alkyl;

a stereoisomer, enantiomer or tautomer thereof, a pharmaceutically acceptable salt thereof, a pharmaceutical composition thereof or a prodrug thereof.

(Previously Presented) The compound of Claim 10 wherein:

x and y are each 1;

W is -O-:

V is -C(O)- or -C(S)-;

 $R^2 \ is \ selected \ from \ the group \ consisting \ of \ C_2\text{--}C_{12} alkenyl, \ C_2\text{--}C_{12} hydroxyalkyl, \ C_2\text{--}C_{12} hydroxyalkyl, \ C_3\text{--}C_{12} cycloalkyl, \ C_4\text{--}C_{12} cycloalkylalkyl, \ aryl, \ C_7\text{--}C_{19} aralkyl, \ C_3\text{--}C_{12} heterocyclyl, \ C_3\text{--}C_{12} heteroaryl, \ and \ C_3\text{--}C_{12} heteroarylalkyl; \$

 $R^{3} \ \text{is selected from the group consisting of C_{1}-$C_{12} alkyl, C_{2}-$C_{12} alkenyl, C_{2}-$C_{12} hydroxyalkyl, C_{2}-$C_{12} hydroxyalkenyl, C_{2}-$C_{12} alkoxyalkyl, C_{3}-$C_{12} cycloalkyl, C_{4}-$C_{12} cycloalkylalkyl, anyl, C_{7}-$C_{12} aralkyl, C_{3}-$C_{12} heterocyclyl, C_{3}-$C_{12} heterocyclylalkyl, C_{1}-$C_{12} heteroanyl and C_{3}-$C_{12} heteroanylalkyl, C_{1}-$C_{12} heteroanylalkyl, C_{1}-$C_{12} heteroanylalkyl, C_{1}-$C_{12} alkyl; $C_$

 $\ensuremath{\mathsf{R}}^4$ and $\ensuremath{\mathsf{R}}^5$ are each hydrogen; and

R⁶, R^{6a}, R⁷, R^{7a}, R⁸, R^{8a}, R⁹ and R^{9a} are each hydrogen.

12. (original) The compound of Claim 11 wherein:

V is -C(O)-:

 $R^2 \text{ is } C_{7^*}C_{12} \text{aralkyl optionally substituted by one or more substituents selected} \\ \text{from halo, cyano, nitro, hydroxy, } C_{1^*}C_6 \text{alkyl, } C_{1^*}C_6 \text{trihaloalkyl and } C_{1^*}C_6 \text{trihaloalkoxy;} \\ \text{}$

 R^3 is phenyl optionally substituted by one or more substituents selected from the group consisting of halo, cyano, nitro, hydroxy, $C_1\text{-}C_0\text{ellkyl},\ C_1\text{-}C_0\text{trihaloalkyy},\ C_1\text{-}C_0\text{ellkyl},\ -N(R^{12})_2,\ -OC(O)R^{12},\ -C(O)OR^{12},\ -S(O)_2N(R^{12})_2,\ \text{cycloalkyl},\ \text{heterocyclyl},\ \text{heteroaryl} and\ \text{heteroarylcycloalkyl};\ \text{and}$

 $each\ R^{12}\ is\ independently\ selected\ from\ hydrogen,\ C_1\text{-}C_8\text{alkyl},\ C_3\text{-}C_6\text{cycloalkyl},$ aryl or aralkyl.

13. (original) The compound of Claim 12 wherein:

 $R^2 is \ C_{7^*} C_{12} aralkyl \ optionally substituted \ by \ one \ or \ more \ substituents \ selected$ from halo, $C_{1^*} C_{8} alkyl$, $C_{1^*} C_{8} trihaloalkyl$ and $C_{1^*} C_{8} trihaloalkoxy$; and

 $R^3 is \ phenyl \ optionally \ substituted \ by \ one \ or \ more \ substituents \ selected \ from \ the group \ consisting \ of \ halo, \ C_1-C_6 trihaloalkyl \ and \ C_1-C_6 trihaloalkoxy.$

- (original) The compound of Claim 13, namely, [4-(6-Phenethyloxy-pyridazin-3-yl)-piperazin-1-yl]-(2-trifluoromethyl-phenyl)-methanone.
 - 15. (original) The compound of Claim 11 wherein:

V is -C(O)-:

R2 is C1-C12alkyl or C2-C12alkenyl;

 R^3 is phenyl optionally substituted by one or more substituents selected from the group consisting of halo, cyano, nitro, hydroxy, $C_1\text{-}C_6\text{alkyl}$, $C_1\text{-}C_6\text{trihaloalkyl}$, $C_1\text{-}C_6\text{trihaloalkyl}$, $-O(O)R^{12}$, $-C(O)OR^{12}$, $-S(O)_2N(R^{12})_2$, cycloalkyl, heterocyclyl, heteroaryl and heteroarylcycloalkyl; and

 $each\ R^{12}\ is\ independently\ selected\ from\ hydrogen,\ C_{\tau^*}C_{\theta}alkyl,\ C_{3^*}C_{\theta}cycloalkyl,$ aryl or aralkyl.

5

16. (original) The compound of Claim 11 wherein:

V is -C(O)-;

R² is C₃-C₁₂cycloalkyl or C₄-C₁₂cycloalkylalkyl;

 R^3 is phenyl optionally substituted by one or more substituents selected from the group consisting of halo, cyano, nitro, hydroxy, $C_1\text{-}C_0\text{ellkyl},\ C_1\text{-}C_0\text{trihaloalky},\ C_1\text{-}C_0\text{frihaloalky},\ C_1\text{-}C_0\text{ellkyl},\ V_1\text{-}V_0\text{R}^{12},\ V_0\text{C}(O)R^{12},\ V_0\text$

each R^{12} is independently selected from hydrogen, C_1 - C_6 alkyl, C_5 - C_6 cycloalkyl, aryl or aralkyl.

17. (original) The compound of Claim 16 wherein:

R2 is C4-C12cycloalkylalkyl; and

 $R^3 \ \text{is phenyl optionally substituted by one or more substituents selected from the group consisting of halo, <math>C_1$ - C_4 trihaloalkyl and C_1 - C_6 trihaloalkoxy.

- 18. (original) The compound of Claim 17, namely, {4-[6-(2-Cyclopropyl-ethoxy)-pyridazin-3-yl]-piperazin-1-yl}-(2-trifluoromethyl-phenyl)-methanone.
 - 19. (Previously Presented) The compound of Claim 10 wherein:

x and y are each 1;

W is -S(O),- (where t is 0, 1 or 2);

V is -C(O)- or -C(S)-;

 $R^2 \text{ is selected from the group consisting of } C_{1^*}C_{12}\text{alkyl}, C_{2^*}C_{12}\text{alkenyl}, \\ C_{2^*}C_{12}\text{hydroxyalkyl}, C_{2^*}C_{12}\text{hydroxyalkenyl}, C_{2^*}C_{12}\text{alkoxyalkyl}, C_{3^*}C_{12}\text{cycloalkyl}, \\ C_{4^*}C_{12}\text{cycloalkylalkyl}, \text{aryl}, C_{7^*}C_{12}\text{aralkyl}, C_{3^*}C_{12}\text{heterocyclyl}, C_{3^*}C_{12}\text{heterocyclylalkyl}, \\ C_{1^*}C_{12}\text{heteroaryl}, \text{and } C_{3^*}C_{12}\text{heteroarylalkyl}; \\$

 R^4 and R^5 are each hydrogen; and R^6 , R^{6a} , R^7 , R^{7a} , R^8 , R^{8a} , R^9 and R^{9a} are each hydrogen.

Docket No.: 17243/004001 Application No.: 10/566,856

20 (original) The compound of Claim 19 wherein:

V is -C(O)-:

R2 is C7-C12 aralkyl optionally substituted by one or more substituents selected from halo, cyano, nitro, hydroxy, C₁-C₆alkyl, C₁-C₆trihaloalkyl and C₁-C₆trihaloalkoxy;

R3 is phenyl optionally substituted by one or more substituents selected from the group consisting of halo, cyano, nitro, hydroxy, C1-Cealkyl, C1-Cetrihaloalkyl, C1-Cetrihaloalkoxy, $C_1 - C_6 \\ alkylsulfonyl, -N(R^{12})_2, -OC(O)R^{12}, -C(O)OR^{12}, -S(O)_2 \\ N(R^{12})_2, \ cycloalkyl, \ heterocyclyl, \$

heteroaryl and heteroarylcycloalkyl; and each R12 is independently selected from hydrogen, C1-C6alkyl, C3-C6cycloalkyl, arvi or aralkyl.

(original) The compound of Claim 20 wherein: 21

R² is C₇-C₁₂aralkyl optionally substituted by one or more substituents selected from halo, C1-C6alkyl, C1-C6trihaloalkyl and C1-C6trihaloalkoxy; and

R³ is phenyl optionally substituted by one or more substituents selected from the group consisting of halo, C₁-C₀trihaloalkyl and C₁-C₀trihaloalkoxy.

(original) The compound of Claim 21 selected from the group consisting of the 22. following:

[4-(6-Phenethylsulfanyl-pyridazin-3-yl)-piperazin-1-yl]-(2-trifluoromethyl-phenyl)-methanone;

{4-[6-(2-Phenyl-ethanesulfinyl)-pyridazin-3-yl]-piperazin-1-yl}-(2-trifluoromethyl-phenyl)methanone: and

{4-[6-(2-Phenyl-ethanesulfonyl)-pyridazin-3-yl]-piperazin-1-yl}-(2-trifluoromethyl-phenyl)methanone.

(original) The compound of Claim 19 wherein: 23

V is -C(O)-:

R2 is C1-C12alkyl or C2-C12alkenyl;

R3 is phenyl optionally substituted by one or more substituents selected from the group consisting of halo, cyano, nitro, hydroxy, C1-C6alkyl, C1-C6trihaloalkyl, C1-C6trihaloalkoxy, $C_1 - C_6 \\ alkylsulfonyl, -N(R^{12})_2, -OC(O)R^{12}, -C(O)OR^{12}, -S(O)_2 \\ N(R^{12})_2, \ cycloalkyl, \ heterocyclyl, -C(O)OR^{12}, -C(O$ heteroarvi and heteroarvicycloalkyl; and

each R12 is independently selected from hydrogen, C1-C8alkyl, C3-C8cycloalkyl,

aryl or aralkyl.

24. (original) The compound of Claim 23 wherein R^3 is phenyl optionally substituted by one or more substituents selected from the group consisting of halo, C_1 - C_6 trihaloalkyl and C_1 - C_6 trihaloalkoxv.

- 25. (original) The compound of Claim 24, namely, {4-[6-{3-Methyl-butylsulfanyl)-pyridazin-3-yl]-piperazin-1-yl}-(2-trifluoromethyl-phenyl)-methanone.
 - 26. (Previously Presented) The compound of Claim 10 wherein:

x and y are each 1;

W is -N(R1)-;

V is -C(O)- or -C(S)-;

R1 is hydrogen or C1-C6alkyl;

 $R^2 \text{ is selected from the group consisting of } C_1\text{-}C_1\text{-}alkyl, } C_2\text{-}C_1\text{-}alkenyl, } C_2\text{-}C_2\text{-}alkenyl, } C_2\text{-}C_2\text{-}alkenyl$

 R^3 is selected from the group consisting of $C_1\text{-}C_{12}$ alkyl, $C_2\text{-}C_{12}$ alkenyl, $C_2\text{-}C_{12}\text{hydroxyalkyl}, C_2\text{-}C_{12}\text{hydroxyalkenyl}, C_2\text{-}C_{12}\text{alkoxyalkyl}, C_3\text{-}C_{12}\text{cycloalkyl}, \\ C_4\text{-}C_{12}\text{cycloalkylalkyl}, \text{aryl}, C_7\text{-}C_{12}\text{aralkyl}, C_3\text{-}C_{12}\text{heterocyclyl}, C_3\text{-}C_{12}\text{heterocyclylalkyl}, \\ C_1\text{-}C_{12}\text{heteroaryl} \text{ and } C_3\text{-}C_{12}\text{heteroarylalkyl}, \text{provided that when V is --C(O)-, } R^3 \text{ is not } C_1\text{-}C_{12}\text{alkyl}; \\$

 R^4 and R^5 are each hydrogen; and $R^6,\ R^{6a},\ R^7,\ R^{7a},\ R^8,\ R^{8a},\ R^9$ and R^{9a} are each hydrogen.

27. (original) The compound of Claim 26 wherein:

V is -C(O)-:

R1 is hydrogen or C1-C6alkyl;

 $R^2 \text{ is } C_{7^*}C_{12} \text{aralkyl optionally substituted by one or more substituents selected} \\ \text{from halo, cyano, nitro, hydroxy, $C_{1^*}C_6$ alkyl, $C_{1^*}C_6$ trihaloalkyl and $C_{1^*}C_6$ trihaloalkoxy;}$

 $R^3 is \ phenyl \ optionally \ substituted \ by \ one \ or \ more \ substituents \ selected \ from \ the \ group \ consisting \ of \ halo, \ cyano, \ nitro, \ hydroxy, \ C_1-C_6 dkyl, \ C_1-C_6 trihaloalkyl, \ C_1-C_6 trihaloalkoxy, \ cyano, \ nitro, \ hydroxy, \ nitro, \ nitro, \ hydroxy, \ nitro, \$

 C_1 - C_6 alkylsulfonyl, -N(R¹²)₂, -OC(O)R¹², -C(O)OR¹², -S(O)₂N(R¹²)₂, cycloalkyl, heterocyclyl, heteroaryl and heteroarylcycloalkyl; and

each R^{12} is independently selected from hydrogen, C_1 - C_6 alkyl, C_3 - C_6 cycloalkyl, aryl or aralkyl.

- 28. (original) The compound of Claim 27 wherein R^3 is phenyl optionally substituted by one or more substituents selected from the group consisting of halo, C_1 - C_6 trihaloalkyl and C_1 - C_6 trihaloalkoxy.
- 29. (original) The compound of Claim 28 selected from the group consisting of the following:

 [4-(6-Phenethylamino-pyridazin-3-yl)-piperazin-1-yl]-(2-trifluoromethyl-phenyl)-methanone: and

(4-(6-(Methyl-phenethyl-amino)-pyridazin-3-yl]-piperazin-1-yl]-(2-trifluoromethyl-phenyl)-

methanone.

30. (original) The compound of Claim 26 wherein:

V is -C(O)-;

R1 is hydrogen or C1-C6alkyl;

R² is C₁-C₁₂alkyl, C₂-C₁₂alkenyl, C₃-C₁₂cycloalkyl or C₄-C₁₂cycloalkylalkyl;

 R^{3} is phenyl optionally substituted by one or more substituents selected from the group consisting of halo, cyano, nitro, hydroxy, $C_{1}\text{-}C_{6}\text{elikyl}$, $C_{1}\text{-}C_{6}\text{trihaloalkyl}$, $C_{1}\text{-}C_{6}\text{trihaloalkyl}$, $C_{1}\text{-}C_{6}\text{trihaloalkyl}$, $C_{1}\text{-}C_{6}\text{trihaloalkyl}$, $C_{1}\text{-}C_{6}\text{trihaloalkyl}$, $C_{1}\text{-}C_{6}\text{trihaloalkyl}$, and heteroaryl cycloalkyl; and

each R^{12} is independently selected from hydrogen, C_1 - C_0 alkyl, C_3 - C_0 cycloalkyl, aryl or aralkyl.

31. (Previously Presented) The compound of Claim 10 wherein:

x and y are each 1;

W is $-N(R^1)S(O)_2$ -;

V is -C(O)- or -C(S)-;

R1 is hydrogen or C1-C6alkyl;

 $R^2 \text{ is selected from the group consisting of } C_1\text{--}C_1\text{-}alkyl, } C_2\text{--}C_1\text{-}alkenyl, } C_2\text{--}C_1\text{--}alkenyl, } C_2\text{--}C$

9

 $C_4 - C_{12} \text{cycloalkylalkyl, aryl, } C_7 - C_{12} \text{aralkyl, } C_3 - C_{12} \text{heterocyclyl, } C_5 - C_{12} \text{heterocyclylalkyl, } \\ C_1 - C_{12} \text{heteroaryl, and } C_3 - C_{12} \text{heteroarylalkyl; } \\$

 $R^3 \text{ is selected from the group consisting of $C_1\text{-}C_{12}\text{alkeyl}$, $C_2\text{-}C_{12}\text{alkenyl}$, $C_2\text{-}C_{12}\text{hydroxyalkyl}$, $C_2\text{-}C_{12}\text{hydroxyalkenyl}$, $C_2\text{-}C_{12}\text{alkexyalkyl}$, $C_3\text{-}C_{12}\text{cycloalkyl}$, $C_3\text{-}C_{12}\text{$

R⁴ and R⁵ are each hydrogen; and R⁶, R^{6a}, R⁷, R^{7a}, R⁸, R^{8a}, R⁹ and R^{9a} are each hydrogen.

32. (original) The compound of Claim 31 wherein:

V is -C(O)-;

R1 is hydrogen or C1-C6alkyl;

 $R^2 \text{ is } C_1\text{-}C_{12}\text{alkyl}, C_2\text{-}C_{12}\text{alkenyl}, C_3\text{-}C_{12}\text{cycloalkyl} \text{ or } C_4\text{-}C_{12}\text{cycloalkylalkyl}; \\ R^3 \text{ is phenyl optionally substituted by one or more substituents selected from the group consisting of halo, cyano, nitro, hydroxy, <math>C_1\text{-}C_6\text{alkyl}, C_1\text{-}C_6\text{trihaloalkyl}, C_1\text{-}C_6\text{trihaloalkyl}, C_1\text{-}C_6\text{trihaloalkyl}, C_1\text{-}C_6\text{trihaloalkyl}, C_1\text{-}C_6\text{cycloalkyl}, heterocyclyl, heteroaryl and heteroarylcycloalkyl; and}$

 $each\ R^{12}\ is\ independently\ selected\ from\ hydrogen,\ C_1\text{-}C_6alkyl,\ C_3\text{-}C_6cycloalkyl,}$ aryl or aralkyl.

33. (original) The compound of Claim 32 wherein:

R2 is C1-C12alkyl; and

 $R^3 \ \text{is phenyl optionally substituted by one or more substituents selected from the group consisting of halo, C_1-C_6 trihaloalkyl and C_1-C_6 trihaloalkoxy.}$

- 34. (original) The compound of Claim 33, namely, Propane-1-sulfonic acid (6-[4-(2-trifluoromethyl-benzoyl)-piperazin-1-yl]-pyridazin-3-yl]-amide.
 - (original) The compound of Claim 31 wherein:

V is -C(O)-;

R1 is hydrogen or C1-C6alkyl;

R² is C₇-C₁₂aralkyl optionally substituted by one or more substituents selected

from halo, cyano, nitro, hydroxy, C1-C6alkyl, C1-C6trihaloalkyl and C1-C6trihaloalkoxy;

 R^3 is phenyl optionally substituted by one or more substituents selected from the group consisting of halo, cyano, nitro, hydroxy, $C_1\text{-}C_0\text{ellkyl},\ C_1\text{-}C_0\text{trihaloalky},\ C_1\text{-}C_1\text{-}C_0\text{ellkyl},\ C_1\text{-}C_0\text{ellkyl},\ C_1\text{-}C_0\text{ellkyl},\ deterocyclyl,\ heterocyclyl,\ heterocyclyl, and heterocyclycloalkyl;\ and$

 $each \ R^{12} \ is \ independently \ selected \ from \ hydrogen, \ C_{1^{\!\!-}}C_{\theta}alkyl, \ C_{3^{\!\!-}}C_{\varepsilon}cycloalkyl,$ aryl or aralkyl.

(Canceled).

- 37. (original) A pharmaceutical composition comprising a pharmaceutically acceptable excipient and a therapeutically effective amount of a compound of Claim 10.
- 38. (New) A method for inhibiting stearoyl-CoA desaturase, comprising contacting a source of stearoyl-CoA desaturase with a compound of claim 1.
- (New) A method for inhibiting stearoyl-CoA desaturase, comprising contacting a source of stearoyl-CoA desaturase with a compound of claim 10.

11